NCT07464756 2026-03-11
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT07371871 2026-01-28
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
Anhui Provincial Cancer Hospital
Phase NA Not yet recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07324473 2026-01-07
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
First Affiliated Hospital of Chongqing Medical University
Phase 2 Not yet recruiting
NCT07314203 2026-01-02
SOP-XH-IRB
Fujian Medical University
Phase 3 Not yet recruiting
NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT07192848 2025-09-25
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 2 Not yet recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT06796803 2025-02-10
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT06759090 2025-01-06
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
Zhejiang University
Phase 2 Not yet recruiting
NCT06632522 2024-10-09
Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
Beijing Tsinghua Chang Gung Hospital
Phase 2 Not yet recruiting
NCT06592287 2024-09-19
The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06538935 2024-08-06
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06482008 2024-07-01
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06464614 2024-06-18
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2 Not yet recruiting
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT05524974 2022-09-01
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
Fujian Medical University
Phase 2 Not yet recruiting